NEW YORK (GenomeWeb News) — The KTH Royal Institute of Technology said today it will use screening technology from Finnish start-up BioSilta Oy for KTH's Human Protein Atlas project.
YouDoBio was also named as the distributor of BioSilta products in Sweden and Denmark.
Terms for neither deal were disclosed.
BioSilta's EnBase technology will be used to accelerate secondary screening of previously poor expressing candidates for the Human Protein Atlas project. In a statement, the two firms said they have been collaborating to optimize protein screening using microwell plates and BioSilta's enzymatic release media technology.
“By combining our knowledge we have been table to develop a very reliable screening method used to determine if a protein could be successfully expressed or not,” KTH professor and Director of Protein Science Sophia Hober said in a statement. KTH is based in Stockholm, Sweden.
“We see a great potential in the EnBase technology and hope other research groups also will find this product beneficial,” Hober added.
BioSilta is based in Oulu, Finland and uses enzymes and biocatalytic activity to advance cell culture technology.